Nasdaq

BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart ...

CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device implantation) and 9% relative risk reduction ...
Business Wire

Ten-Year APHINITY Data Show Genentech’s Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support ...
Renal & Urology News

Prostate Cancer-Related Mortality Risk Differs Among Lymph Node-Positive Subgroups

Patients with advanced pathologic stage, a higher number of positive lymph nodes, and positive surgical margins had the highest risks of dying from prostate cancer. Lymph node positive (pN1) prostate ...
Business Wire

New England Journal of Medicine Publishes Landmark Phase III Results for Genentech’s Itovebi, Showing More Than Doubling of Progression-Free Survival in Certain Type of HR ...

– Itovebi TM (inavolisib)-based regimen demonstrated a statistically significant and clinically meaningful benefit, reducing the risk of disease worsening or death by 57% compared with palbociclib and ...
Healio

Trastuzumab deruxtecan shows ‘encouraging real-world outcomes’ for metastatic breast cancer

Please provide your email address to receive an email when new articles are posted on . Patients with HER2-positive metastatic breast cancer had a real-world PFS of 1 year on trastuzumab deruxtecan.